Table 1.
Baseline values of the T2DM patients enrolled in the study
| Parameters | Met+placebo, n=20 | Met+GKB, n=27 | P-value |
|---|---|---|---|
| Age (years) | 48.2±10.3 | 48.7±9.6 | 0.85 |
| Male (%) | 3 (15) | 5 (17.2) | 0.42 |
| Weight (kg) | 83.4±12.2 | 82.7±17 | 0.88 |
| BMI (kg/m2) | 34.2±6.2 | 33.9±6.0 | 0.8 |
| WC (cm) | 103.9±9.7 | 105.8±10.9 | 0.54 |
| VAI | 196.5±82.8 | 191.8±86.2 | 0.85 |
| Diabetes duration (years) | 2.93±2.1 | 3.52±3.1 | 0.47 |
| Met therapy | |||
| Duration of use (months) | 28±26.2 | 40.9±38.4 | 0.2 |
| Daily dose (g) | 1.24±0.67 | 1.36±0.45 | 0.45 |
| Laboratory data | |||
| HbA1c (%) | 8.8±2.3 | 8.6±1.6 | 0.69 |
| FSG (mg/dL) | 166.7±56.8 | 194.4±66.1 | 0.14 |
| Serum insulin (μU/mL) | 17.5±8.1 | 18.5±8.9 | 0.72 |
| Insulin resistance | 9.4±7.1 | 9.0±5.3 | 0.83 |
Note: Values are presented as mean±SD.
Abbreviations: BMI, body mass index; FSG, fasting serum glucose; GKB, Ginkgo biloba; HbA1c, glycated hemoglobin; Met, metformin; T2DM, type 2 diabetes mellitus; VAI, visceral adiposity index; WC, waist circumference.